Skip to content

Botulinum toxin type E

Botulinum toxin type E is a serotype, a biologically distinct type within the botulinum toxin family. Its medical-product role includes Boey (trenibotulinumtoxinE), developed by Allergan Aesthetics, an AbbVie company, for temporary improvement of moderate to severe glabellar lines, the vertical frown lines between the eyebrows. Boey has a rapid-onset, short-duration profile under its regional approvals (AbbVie European approval announcement 🔗).

Type E should still be separated from a specific product. TrenibotulinumtoxinE is one medical preparation with its own dose units, clinical program, region-specific approved indication, and regulatory history. Results reported for that preparation do not establish that every type E toxin would have the same clinical profile.

Type E reduces release of acetylcholine, the chemical messenger that tells muscles to contract, by cleaving SNAP-25. This protein is part of the SNARE machinery that helps nerve endings release chemical signals. Type A also acts on SNAP-25, but the two serotypes cleave the protein at different sites. Experimental research shows that the resulting fragments interact differently with the nerve ending’s signal-release machinery; this helps explain biological differences without predicting an individual treatment’s duration (Bajohrs et al., EMBO Reports 🔗).

That shared target does not make type A and type E interchangeable. Serotype, preparation, formulation, potency assay, dose units, clinical evidence, and regulatory label all remain distinct. The broader signaling sequence is covered in botulinum toxin mechanism of action.

TrenibotulinumtoxinE, also called TrenibotE during development, was evaluated in two pivotal randomized, double-blind, placebo-controlled Phase 3 studies, M21-500 and M21-508. AbbVie reported 947 adults across the United States, Canada, and Europe, including people with and without previous toxin treatment (AbbVie Phase 3 topline announcement 🔗).

A peer-reviewed report of one pivotal Phase 3 study, published on October 24, 2026, adds detail beyond the initial company announcement. At day seven, 60.0% of trenibotulinumtoxinE recipients versus 0.6% of placebo recipients met a combined endpoint: both investigator and participant rated the lines as absent or mild, with at least a two-grade improvement at maximum frown. Improvement was observed from eight hours, peaked at day seven, and line severity returned to moderate or severe by day 21 (Burgess et al.: pivotal trenibotulinumtoxinE study, Aesthetic Surgery Journal 🔗).

EMA’s overview reports a different analysis from the two main studies: among 725 adults whose lines had a psychological impact, investigators rated 72.6% of Boey recipients versus 0.5% of placebo recipients as having absent or mild lines with at least a two-grade improvement at day seven. That figure and the publication’s combined investigator-and-participant endpoint describe different analyses; they are not competing estimates of the same outcome (EMA Boey clinical overview 🔗).

Eight hours was the earliest assessment in the pivotal program, not a guarantee of full effect by that time. The regional product information describes a response lasting approximately two to three weeks and occasional use. Duration is not a retreatment interval. These findings apply to the studied preparation and glabellar-line setting; placebo comparisons do not establish superiority over an active type A product (AbbVie Phase 3 announcement 🔗, AEMPS Boey product information, sections 4.2 and 5.1 🔗).

AbbVie is also studying trenibotulinumtoxinE combined with onabotulinumtoxinA, the type A ingredient in Botox. The recruiting Phase 2 study M26-312 (ClinicalTrials.gov: NCT07871513 🔗) records an actual start on October 8, 2026, and planned enrollment of 300 adults with moderate to severe upper facial lines. It evaluates the two toxins co-reconstituted, meaning prepared together in one solution; part one concerns glabellar lines.

The study includes onabotulinumtoxinA-alone and placebo comparator groups. Its primary measures include adverse events through day 150 and investigator-assessed glabellar-line response at day seven. The registry has no posted results, so the design does not establish combination efficacy, safety, regulatory approval, or a unit-conversion ratio between the ingredients (ClinicalTrials.gov: M26-312 design and outcomes 🔗).

A separate Project Skin MD pilot study, NCT07923448 on ClinicalTrials.gov 🔗, was first posted on November 6, 2026. It asks whether trenibotulinumtoxinE given after onabotulinumtoxinA can shorten the type A effect in lateral canthal lines, commonly called crow’s feet. The record lists Phase 2, an estimated four participants, and a not-yet-recruiting status, with a planned December 2026 start.

The proposed split-face comparison gives each participant type A on both sides, followed by type E on one randomly assigned side and placebo on the other. The main outcome is the time until line severity returns to its pretreatment level on each side. This sequential design differs from AbbVie’s co-reconstituted combination trial. No results are posted, and the registration does not establish that type E reverses Botox effects or provides an approved reversal treatment (ClinicalTrials.gov: PS01-treni design and outcomes 🔗).

RegionStatusInterpretation
CanadaHealth Canada’s innovative-drug register 🔗 records a June 22, 2026 notice of compliance. Its Drug Product Database entry for Boey 🔗 lists marketed status and an original market date of October 5, 2026.Authorization and commercial introduction are separate milestones. Canadian product information controls the authorised use.
European Union / EEAEMA records EU marketing authorization on July 15, 2026 🔗. AbbVie announced the decision on July 17 and described authorization across the EEA.France’s public medicines database entry for Boey 🔗 records a commercialization declaration dated October 1, 2026. This does not establish a launch in every EEA country.
United StatesAbbVie reported an FDA Complete Response Letter (CRL) for the biologics license application (BLA) on April 23, 2026. Its Q3 2026 Form 10-Q, filed November 3 🔗, reiterates the manufacturing-process information request and says no additional clinical studies were requested.Boey is not FDA approved. In the October 30 earnings call, management anticipated resubmission at the end of 2026 and a decision in mid-2027, according to the published AbbVie Q3 transcript — The Motley Fool 🔗. These remain company expectations, not a completed or accepted resubmission or an FDA-assigned deadline.

The EEA indication is temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown when the lines have an important psychological impact in adults (EMA Boey indication 🔗). That wording is region-specific and should not be treated as a U.S. approval or a general indication for type E.

The current U.S. stage is summarized with other approved and non-approved programs in U.S. botulinum toxin regulatory status.

The EU presentation contains 1,400 units of trenibotulinumtoxinE as powder for solution for injection. Its potency units are not interchangeable with those of other botulinum toxin products (AEMPS Boey product information, sections 2 and 4.2 🔗). That vial number does not place Boey on a shared potency scale with Botox, Dysport, Xeomin, type B products such as Myobloc, or another preparation.

Product-specific potency units do not provide a universal conversion into type A or type B units. Their numerical size alone does not establish greater strength, spread, duration, or clinical value.

Short duration does not remove toxin-related risks. Boey’s EU product information warns about effects beyond the injection site, including potentially serious swallowing or breathing difficulties, and interactions with other medicines that affect nerve-to-muscle signaling (EMA Boey product information, sections 4.4 and 4.5 🔗).

The EU label states that simultaneous administration with another botulinum toxin has not been investigated and should be prohibited. It also states that retreatment more frequently than every six weeks has not been evaluated. A two-to-three-week clinical effect therefore does not establish a repeat-treatment schedule, and the investigational combined and sequential programs do not change the approved conditions of use (EMA Boey product information, sections 4.2 and 4.4 🔗).

Type E adds a medically regulated product category beyond the established type A and type B markets. TrenibotulinumtoxinE’s rapid-onset, short-duration profile supports a distinct product role. Co-reconstituted treatment and sequential treatment after type A explore different research questions; neither establishes a clinical ranking between serotypes or a proven reversal option.

Clinical value depends on the patient’s treatment goal, product label, evidence, safety profile, and regulatory availability; shorter duration is not inherently better.

1. What can Boey's short-duration clinical results establish about type E?
2. What do Boey's Canadian marketed status and French commercialization records establish?
3. A pilot study will compare type E with placebo after type A treatment. What can be concluded before results are available?
4. What does a larger unit number on a toxin vial tell a reader?